Nature Medicine, Published online: 21 October 2025; doi:10.1038/s41591-025-04002-0
The first-in-human trial of AAV2i8-I1c (AB-1002) — an adenovirus vector that targets a protein phosphatase inhibitor to cardiac muscle — suggests a cautious return of cardiac gene therapy after earlier setbacks, with a new target, dose optimization and improved vector design shaping future directions.
